Nycomed agent gets FDA approvable note

By AuntMinnie.com staff writers

February 29, 2000 --

The Nycomed Amersham Imaging agent Myoview may soon be used to assess coronary artery disease in patients who are unable to physically exert themselves, according to the Princeton, NJ, company.

The Food and Drug Administration has issued an approvable letter for use of the technetium Tc-99m preparation kit with pharmacological stress agents. The company submitted the application to the FDA 10 months ago and will now work toward market approval, said Dr. John Padfield, CEO of Nycomed Amersham Imaging. Myoview is already in use for cardiac perfusion imaging.

By AuntMinnie.com staff writers
February 29, 2000


Copyright © 2000 AuntMinnie.com
 
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: